Kuros Skyrockets with 163% Surge in MagnetOs Sales, 153% Jump in Total Medical Device Sales in 2023

• Kuros Biosciences reported a 163% growth in direct MagnetOs sales, reaching CHF 31.7 million in 2023, up from CHF 12.1 million in 2022.
• Total medical device sales increased by 153%, from CHF 13.3 million in 2022 to CHF 33.6 million in 2023.
• The Medical Devices segment achieved a positive EBITDA of CHF 6.8 million, driven by MagnetOs.
• Cash and cash equivalents amounted to CHF 14.2 million and funds available totaled at CHF 21.8 million as of December 31, 2023.
• MagnetOs surpassed the milestone of 25,000 patients treated and received FDA market clearance for interbody use of several products.
• Kuros expects a similar sales growth trend going forward and plans to generate positive single-digit EBITDA for the first time in 2024.

The next important date, Quarterly report, at Kuros Biosciences is on 13.03.2024.

Kuros Biosciences

+0,07 %

-9,03 %

+16,17 %

+44,88 %

+494,90 %

+275,60 %

+278,99 %

-68,43 %

ISIN:CH0325814116WKN:A2ALS5

• Intraday
• 5 Tage
• 1 Monat
• 3M
• 1 Jahr
• 3J
• 5J
• Max